Our institute is developing colistin screening agar (2.0ug/ml) for Pseudomonas and Acinetobacter spp in routine setting. May we know if there is any concern with submission to LOINC?
The new test would have the fully-specified name:
Colistin 2ug/mL [Susceptibility] by Method for Pseudomonas and Acinetobacter
Reference to naming convention and existing LOINC concept: [60564-2] Amikacin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria
Please advise at your earliest convenience. Thank you very much.